[Federal Register Volume 62, Number 69 (Thursday, April 10, 1997)]
[Notices]
[Page 17630]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-9237]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Propspective Grant of Exclusive License: Method of Identifying 
Persons Susceptible to Autoimmune Neuropsychiatric Disorders

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice its interest in the invention embodied 
in U.S. Patent Application Serial No. 08/473,033, filed June 6, 1995, 
entitled, ``Method of Identifying Persons Susceptible to Autoimmune 
Neuropsychiatric Disorders,'' and subsequent filings, to Callisto 
Pharmaceuticals, Inc., having a place of business in New York, New 
York. The United States is a joint assignee of the patent rights in 
these inventions.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
the prospective exclusive license may be granted unless, within 90 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use would be diagnosing persons with, or at risk of 
developing, certain neuropsychiatric disorders as described in the 
patent application.

SUPPLEMENTARY INFORMATION: Obsessive compulsive disorder is a severe 
debilitating condition that can interfere dramatically with daily 
activities. Obsessive thoughts can include worries about either 
personal or family safety, past actions, or fears of contamination. 
Currently there is no known biologic or genetic marker diagnostic for 
this disorder. However, there is evidence that certain autoimmune 
diseases have accompanying psychological symptoms including obsessive 
compulsive behavior, attention deficit hyperactivity disorder, 
emotional lability, and irritability. The patent application relates to 
the discovery that in patients at risk for developing neuropsychiatric 
disorders due to autoimmune disease there is a dramatic increase in the 
number of B lymphocytes expressing an alloantigen. Detection of the 
antigen has been shown to be predictive for obsessive compulsive 
behavior. In addition, individuals at genetic risk for these 
neuropsychiatric disorders can also be identified.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Leopold J. Luberecki, Jr., J.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 
20852-3804; Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-
0220. Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Only written comments and/or application for a 
license which are received by the NIH Office of Technology Transfer on 
or before July 9, 1997 will be considered.
    Comments and objections submitted in response to this notice will 
not be made available for public inspection, and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: March 31, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-9237 Filed 4-9-97; 8:45 am]
BILLING CODE 4140-01-M